Legal Representation
Attorney
Joi A. White
USPTO Deadlines
Next Deadline
21 days remaining
Non-Final Action Mailed
Due Date
August 07, 2025
Extension Available
Until November 07, 2025
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
15 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| May 7, 2025 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| May 7, 2025 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| May 7, 2025 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Apr 9, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Apr 8, 2025 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Apr 8, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jan 8, 2025 | XELG | O | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | Loading... |
| Jan 8, 2025 | XELR | I | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | Loading... |
| Oct 10, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Oct 10, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Oct 10, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Oct 9, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Apr 2, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Mar 28, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Mar 28, 2024 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceuticals for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; pharmaceutical preparations for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; pharmaceutical substances for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; therapeutics for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; therapeutic agents for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; gene therapy systems used to express therapeutic proteins in vivo for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; biopharmaceuticals for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; medicines for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; drugs for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; vaccines; in vivo cell therapies for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; cells for medical or clinical use; stem cells for medical purposes; cells for medical use; genetically engineered cells for medical purposes; gene therapy products, namely, lipid nanoparticle encapsulated nucleic acids; gene therapy preparations, in the nature of lipid nanoparticle encapsulated nucleic acids; gene therapy pharmaceutical preparations for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; gene therapy products, namely, genetically engineered cells for transplant purposes; targeted in vivo RNA technologies for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; targeted lipid nanoparticles for medicinal use; targeted lipid nanoparticles for durable cell reprogramming or cell engineering; targeted lipid nanoparticles for transient cell reprogramming or cell engineering; cell engineering platforms for treatment of human diseases, disorders and conditions; cell platforms for treatment of human diseases, disorders and conditions; technology platforms for developing and engineering therapeutic cells for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; in vivo cell engineering platforms for developing and engineering therapeutic cells, transient gene therapy, and durable gene therapy for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; transient in vivo cell engineering platforms for durable gene therapy for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders;
Classification
International Classes
005
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"THERAPEUTICS"